
FDA Approves First At-Home Treatment for Acute Agitation
The FDA approved at-home dexmedetomidine film for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
The US Food and Drug Administration (FDA) approved dexmedetomidine sublingual film (Igalmi, Teva) for self-administration at home to treat acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, Teva announced November 16, 2026. It is the first FDA-approved treatment for at-home use during acute agitation episodes associated with these conditions.¹˒²
The approval expands use of the central α₂-adrenergic receptor agonist beyond health care–supervised settings. The recommended at-home dose is 120 mcg, with at least 12 hours between doses if agitation recurs. The updated prescribing information recommends against unsupervised use in adults aged 65 years or older and in patients with hepatic impairment of any severity.²
What evidence supported at-home dexmedetomidine use?
The approval was supported by the phase 3 SERENITY At-Home trial (NCT05658510), a 12-week, randomized, double-blind, placebo-controlled study of self-administered dexmedetomidine 120 mcg. Of the 208 adults who received study treatment, 102 received dexmedetomidine and 106 received placebo. Among treated participants, 53% had agitation associated with schizophrenia or schizoaffective disorder and 47% had agitation associated with bipolar I or II disorder.¹˒²
Patients assigned to dexmedetomidine treated 1,160 agitation episodes. Teva reported that the trial met its primary safety and tolerability endpoint, that tolerability remained consistent with repeat dosing, and that no patients discontinued dexmedetomidine because of tolerability. The earlier SERENITY I and II trials established efficacy in supervised settings using change in the Positive and Negative Syndrome Scale–Excited Component score at 2 hours.¹˒²
How is dexmedetomidine dosed at home?
Patients self-administer one 120-mcg film sublingually or buccally during an episode. If agitation recurs, an additional 120-mcg dose may be taken at least 12 hours after the previous dose, with a limit of 1 dose per 12-hour period. The 180-mcg strength is reserved for supervised use.²
The indication covers acute episodes. Patients should continue treatment for the underlying psychiatric disorder, and frequent use of dexmedetomidine should prompt reassessment of that regimen.²
What safety risks should primary care physicians review?
The prescribing information calls for assessing heart rate, blood pressure, including orthostatic measurements, and the risk of syncope and falls before treatment. Dexmedetomidine can cause hypotension, orthostatic hypotension, and bradycardia. The label advises avoiding use in patients with these blood pressure conditions, advanced heart block, severe ventricular dysfunction, a history of syncope, or risk factors for QT prolongation. It also advises avoiding concomitant QT-prolonging drugs and, in the unsupervised setting, sedatives, hypnotics, and opioids.²
In the at-home trial, somnolence, including fatigue and sedation, was reported in 55% of dexmedetomidine recipients and 42% of placebo recipients. Dry mouth occurred in 15% vs 4%, dizziness in 11% vs 3%, and oral paresthesia or hypoesthesia in 5% vs 2%, respectively. The label advises patients to sit or lie down after dosing, rise slowly, and avoid driving or other activities requiring alertness for at least 8 hours.²
When will at-home dexmedetomidine be available?
Teva said it would announce commercialization plans for at-home use at a later date. The November 16 announcement did not specify a launch date.¹
References
- Teva Pharmaceuticals. FDA approval of Igalmi for at-home treatment of acute agitation in adults. News release. November 16, 2026.
Teva announcement - Igalmi (dexmedetomidine) sublingual film. Prescribing information. Teva Neuroscience Inc. Revised November 2026.
Full prescribing information
Related to this article








